The GLP-1 Bridge Program: Price Fixing vs. Free Market Healthcare
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
The GLP-1 Bridge Program: Price Fixing vs. Free Market Healthcare
-
Narrated by:
-
Written by:
In this episode of the Health Policy Podcast, host Brian Hyde speaks with Jay Goldberg, North American Affairs Manager at the Consumer Choice Center, about the GLP-1 Bridge Program. While the program aims to make weight loss drugs like GLP-1s more affordable for Medicare and Medicaid recipients, Goldberg argues it exemplifies government price fixing. He explains how artificially lowering drug prices can disincentivize medical innovation and lead to slower access to new medications, drawing parallels to healthcare systems in other countries. Goldberg advocates for free-market competition as the most effective and sustainable way to reduce drug costs and foster innovation, ultimately benefiting consumers and the healthcare system more broadly.